MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net
$9,863,883
Proceeds from exercise of
warrants and stock...
$605
Net cash provided by
financing activities
$9,864,488
Net (decrease)
increase in cash, cash...
-$2,149,593
Canceled cashflow
$9,864,488
Other receivables
-$977,303
Deferred revenue
$974,799
Stock-based compensation
$537,540
Net cash used in
operating activities
-$12,014,081
Canceled cashflow
$2,489,642
Net loss
-$12,163,620
Related party payable
-$1,710,500
Accounts payable and
accrued expenses
-$454,570
Prepaid expenses and
deposits
$175,033
Back
Back
Cash Flow
source: myfinsight.com
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)